Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
9,484
Not yet recruiting, any sponsor type
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting22,408
- Not yet recruiting9,484
- Completed134,382
9,484 trials
Showing 1 to 25, recently updated first.
- Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.Pivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07951411 · 240 participants (planned) · Start Dec 31, 2026 · Primary completion Jul 30, 2027
Drug: SAL0167 Dose 1; SAL0167 Dose 2 and 2 more · For: Hyperlipidemia
Sites: Beijing, China
- Human Experimental Models of Pain (HEMP)Not yet recruiting
National Center for Complementary and Integrative Health (NCCIH)NIH
NCT07549490 · 25 participants (planned) · Start Nov 25, 2026 · Primary completion Dec 31, 2029
Drug: Placebo; Naproxen and 1 more · For: Acute Pain
Sites: Bethesda, Maryland
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromePivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07569081 · 136 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 19, 2028
Drug: Momelotinib; Glucocorticoids and 1 more · For: VEXAS Syndrome
Sites: Houston, Texas; Salzburg, Austria; Tokyo, Japan
Triastek, lnc.Industry
NCT07951138 · 18 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 19, 2026
Drug: Itraconazole Tablet(T26); Sporanox® · For: Fungal Infections
Sites: Chongqing, China
- Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac DiseasePivotal-lookingNot yet recruiting
Interlude Biopharma Co.Industry
NCT07944625 · 414 participants (planned) · Start Feb 2027 · Primary completion Aug 2028
Drug: Larazotide Acetate; Placebo · For: Celiac Disease; Celiac Disease in Adolescents
- ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast CancerNot yet recruiting
Jin Sun BitarAcademic, hospital or other
NCT07950007 · 60 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 1, 2029
Drug: T-DXd · For: HER2 + Breast Cancer
Sites: Beverly Hills, California
- Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)Not yet recruiting
IRCCS Policlinico S. DonatoAcademic, hospital or other
NCT07951749 · 16 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 31, 2027
Drug: Berotralstat · For: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Sites: Milan, Italy; San Donato Milanese, Italy; Naples, Italy · 7 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07703514 · 60 participants (planned) · Start Dec 11, 2026 · Primary completion Apr 12, 2027
Drug: cH15/3; cH4/3 and 3 more · For: Influenza
Sites: Baltimore, Maryland
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardPivotal-lookingNot yet recruiting
University of MinnesotaAcademic, hospital or other
NCT06977438 · 1,020 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2031
Drug: Semaglutide · For: Obesity, Childhood
Sites: Minneapolis, Minnesota
- Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube LubricationPivotal-lookingNot yet recruiting
Beijing Tsinghua Chang Gung HospitalAcademic, hospital or other
NCT07950839 · 120 participants (planned) · Start Nov 4, 2026 · Primary completion Mar 4, 2027
Drug: Lidocaine Cream 5% · For: Postoperative Throat Numbness; Post-intubation Throat Symptoms
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07796373 · 32 participants (planned) · Start Nov 25, 2026 · Primary completion Dec 1, 2030
Drug: Nemtabrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
Sites: Bethesda, Maryland
- A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid TumorsNot yet recruiting
BioNTech SEIndustry
NCT07951359 · 345 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: BNT3211 · For: Advanced Solid Tumor
- Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07715903 · 20 participants (planned) · Start Nov 25, 2026 · Primary completion Dec 31, 2029
Drug: Carfilzomib · For: Colorectal Neoplasms; Neoplasms; Intrahepatic Cholangiocarcinoma and 2 more
Sites: Bethesda, Maryland
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07950332 · 200 participants (planned) · Start Dec 2026 · Primary completion Dec 1, 2028
Drug: HRS-7172 tablet; HRS-7172; SHR-4610 ; chemotherapy and 1 more · For: Lung Cancer
Sites: Beijing, China; Hangzhou, China
- Comparing Itraconazole Alone With Itraconazole Plus Terbinafine for Adults With Resistant Tinea CorporisPivotal-lookingNot yet recruiting
Sheikh Zayed Medical CollegeGovernment (non-federal)
NCT07951476 · 104 participants (planned) · Start Dec 2026 · Primary completion Jun 2027
Drug: itraconazole; Itraconazole + terbinafine · For: Tinea Corporis; Resistant Dermatophyte Infection
- Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.Not yet recruiting
University of California, San DiegoAcademic, hospital or other
NCT07923760 · 62 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2031
Drug: Supplemental Oxygen · For: Sleep-disordered Breathing; Chronic Opioid Use
Sites: La Jolla, California
- A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07951463 · 375 participants (planned) · Start Dec 31, 2026 · Primary completion Apr 30, 2029
Drug: Glumetinib Tablets; Placebo and 3 more · For: Non-small Cell Lung Cancer
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07951515 · 1,188 participants (planned) · Start Dec 21, 2026 · Primary completion Nov 19, 2029
Drug: MK-8748; Aflibercept · For: Retinal Vein Occlusion; Macular Edema
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruiting
National Cancer Institute (NCI)NIH
NCT07756840 · 50 participants (planned) · Start Nov 25, 2026 · Primary completion Jul 1, 2029
Drug: PRGN-2012; Bevacizumab · For: Respiratory Recurrent Papillomatosis (RRP); Human Papillomavirus (HPV); Papillomavirus Infection and 3 more
Sites: Bethesda, Maryland
- Safty and Efficacy of KH658 in Subjects With Diabetic RetinopathyNot yet recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT07951606 · 48 participants (planned) · Start Feb 2027 · Primary completion Jun 2028
Drug: Ranibizumab · For: Diabetic Retinopathy
Sites: Beijing, China; Chengdu, China
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07951762 · 368 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2028
Drug: SYS6043+PD-1/VEGF bispecific antibody; SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy. and 1 more · For: Advanced Solid Tumor
- Posterior Default Network Modulation in Alcohol Use DisorderNot yet recruiting
Indiana UniversityAcademic, hospital or other
NCT07951736 · 70 participants (planned) · Start Jan 2027 · Primary completion Jun 2031
Drug: IV alcohol solution · For: Alcohol Use Disorder
Sites: Indianapolis, Indiana
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid ArthritisNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07951086 · 96 participants (planned) · Start Jan 26, 2027 · Primary completion May 18, 2028
Drug: DDY391; Placebo · For: Rheumatoid Arthritis
- Allogeneic iNKT Cells in AS: Immune Remodeling StudyNot yet recruiting
Chinese PLA General HospitalAcademic, hospital or other
NCT07951632 · 12 participants (planned) · Start Nov 2026 · Primary completion Apr 16, 2028
Drug: Allogeneic iNKT Cells · For: Ankylosing Spondylitis
Sites: Beijing, China
- A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or ObesityNot yet recruiting
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT07950462 · 40 participants (planned) · Start Jan 13, 2027 · Primary completion Oct 29, 2027
Drug: QLS7402 Injection; Placebo control · For: Overweight or Obesity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.